AAAAAA
Results:
1-13
|
Results: 13
Authors:
Buzaid, AC
Atkins, M
Citation: Ac. Buzaid et M. Atkins, Practical guidelines for the management of biochemotherapy-related toxicity in melanoma, CLIN CANC R, 7(9), 2001, pp. 2611-2619
Authors:
Balch, CM
Buzaid, AC
Soong, SJ
Atkins, MB
Cascinelli, N
Coit, DG
Fleming, ID
Gershenwald, JE
Houghton, A
Kirkwood, JM
McMasters, KM
Mihm, MF
Morton, DL
Reintgen, DS
Ross, MI
Sober, A
Thompson, JA
Thompson, JF
Citation: Cm. Balch et al., Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma, J CL ONCOL, 19(16), 2001, pp. 3635-3648
Authors:
Ekmekcioglu, S
Ellerhorst, J
Smid, CM
Prieto, VG
Munsell, M
Buzaid, AC
Grimm, EA
Citation: S. Ekmekcioglu et al., Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival, CLIN CANC R, 6(12), 2000, pp. 4768-4775
Authors:
Grimm, EA
Smid, CM
Lee, JJ
Tseng, CH
Eton, O
Buzaid, AC
Citation: Ea. Grimm et al., Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy, CLIN CANC R, 6(10), 2000, pp. 3895-3903
Authors:
Gershenwald, JE
Buzaid, AC
Ross, MI
Citation: Je. Gershenwald et al., Classification and staging of melanoma, CLIN LAB M, 20(4), 2000, pp. 785
Authors:
Gershenwald, JE
Fischer, D
Buzaid, AC
Citation: Je. Gershenwald et al., Clinical classification and staging, CLIN PLAST, 27(3), 2000, pp. 361
Authors:
Eton, O
Buzaid, AC
Bedikian, AY
Smith, TM
Papadopoulos, NE
Ellerhorst, JA
Hibberts, JL
Legha, SS
Benjamin, RS
Citation: O. Eton et al., A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy, CANCER, 88(7), 2000, pp. 1703-1709
Authors:
Balch, CM
Buzaid, AC
Atkins, MB
Cascinelli, N
Coit, DG
Fleming, ID
Houghton, A
Kirkwood, JM
Mihm, MF
Morton, DL
Reintgen, D
Ross, MI
Sober, A
Soong, SJ
Thompson, JA
Thompson, JF
Gershenwald, JE
McMasters, KM
Citation: Cm. Balch et al., A new American Joint Committee on Cancer staging system for cutaneous melanoma, CANCER, 88(6), 2000, pp. 1484-1491
Authors:
Ellerhorst, JA
Bedikian, A
Ring, S
Buzaid, AC
Eton, O
Legha, SS
Citation: Ja. Ellerhorst et al., Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy, ONCOL REP, 6(5), 1999, pp. 1097-1099
Authors:
Ekmekcioglu, S
Okcu, MF
Colome-Grimmer, MI
Owen-Schaub, L
Buzaid, AC
Grimm, EA
Citation: S. Ekmekcioglu et al., Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10, MELANOMA RE, 9(3), 1999, pp. 261-272
Authors:
Bedikian, AY
Legha, SS
Eton, O
Buzaid, AC
Papadopoulos, N
Plager, C
McIntyre, S
Viallet, J
Citation: Ay. Bedikian et al., Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma, ANTI-CANC D, 10(8), 1999, pp. 735-739
Authors:
Poo-Hwu, WJ
Ariyan, S
Lamb, L
Papac, R
Zelterman, D
Hu, GL
Brown, J
Fischer, D
Bolognia, J
Buzaid, AC
Citation: Wj. Poo-hwu et al., Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma, CANCER, 86(11), 1999, pp. 2252-2258
Authors:
Buzaid, AC
Colome, M
Bedikian, A
Eton, O
Legha, SS
Papadopoulos, N
Plager, C
Ross, M
Lee, JE
Mansfield, P
Rice, J
Ring, S
Lee, JJ
Strom, E
Benjamin, R
Citation: Ac. Buzaid et al., Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases, MELANOMA RE, 8(6), 1998, pp. 549-556
Risultati:
1-13
|